Cargando…

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Detalles Bibliográficos
Autores principales: Hortobagyi, G N, Stemmer, S M, Burris, H A, Yap, Y S, Sonke, G S, Paluch-Shimon, S, Campone, M, Petrakova, K, Blackwell, K L, Winer, E P, Janni, W, Verma, S, Conte, P, Arteaga, C L, Cameron, D A, Mondal, S, Su, F, Miller, M, Elmeliegy, M, Germa, C, O’Shaughnessy, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927326/
https://www.ncbi.nlm.nih.gov/pubmed/31407010
http://dx.doi.org/10.1093/annonc/mdz215
_version_ 1783482285915373568
author Hortobagyi, G N
Stemmer, S M
Burris, H A
Yap, Y S
Sonke, G S
Paluch-Shimon, S
Campone, M
Petrakova, K
Blackwell, K L
Winer, E P
Janni, W
Verma, S
Conte, P
Arteaga, C L
Cameron, D A
Mondal, S
Su, F
Miller, M
Elmeliegy, M
Germa, C
O’Shaughnessy, J
author_facet Hortobagyi, G N
Stemmer, S M
Burris, H A
Yap, Y S
Sonke, G S
Paluch-Shimon, S
Campone, M
Petrakova, K
Blackwell, K L
Winer, E P
Janni, W
Verma, S
Conte, P
Arteaga, C L
Cameron, D A
Mondal, S
Su, F
Miller, M
Elmeliegy, M
Germa, C
O’Shaughnessy, J
author_sort Hortobagyi, G N
collection PubMed
description
format Online
Article
Text
id pubmed-6927326
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-69273262019-12-27 Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer Hortobagyi, G N Stemmer, S M Burris, H A Yap, Y S Sonke, G S Paluch-Shimon, S Campone, M Petrakova, K Blackwell, K L Winer, E P Janni, W Verma, S Conte, P Arteaga, C L Cameron, D A Mondal, S Su, F Miller, M Elmeliegy, M Germa, C O’Shaughnessy, J Ann Oncol Corrigenda Oxford University Press 2019-11 2019-08-13 /pmc/articles/PMC6927326/ /pubmed/31407010 http://dx.doi.org/10.1093/annonc/mdz215 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Corrigenda
Hortobagyi, G N
Stemmer, S M
Burris, H A
Yap, Y S
Sonke, G S
Paluch-Shimon, S
Campone, M
Petrakova, K
Blackwell, K L
Winer, E P
Janni, W
Verma, S
Conte, P
Arteaga, C L
Cameron, D A
Mondal, S
Su, F
Miller, M
Elmeliegy, M
Germa, C
O’Shaughnessy, J
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
title Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
title_full Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
title_fullStr Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
title_full_unstemmed Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
title_short Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
title_sort updated results from monaleesa-2, a phase iii trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, her2-negative advanced breast cancer
topic Corrigenda
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927326/
https://www.ncbi.nlm.nih.gov/pubmed/31407010
http://dx.doi.org/10.1093/annonc/mdz215
work_keys_str_mv AT hortobagyign updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer
AT stemmersm updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer
AT burrisha updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer
AT yapys updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer
AT sonkegs updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer
AT paluchshimons updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer
AT camponem updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer
AT petrakovak updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer
AT blackwellkl updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer
AT winerep updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer
AT janniw updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer
AT vermas updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer
AT contep updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer
AT arteagacl updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer
AT cameronda updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer
AT mondals updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer
AT suf updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer
AT millerm updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer
AT elmeliegym updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer
AT germac updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer
AT oshaughnessyj updatedresultsfrommonaleesa2aphaseiiitrialoffirstlineribociclibplusletrozoleversusplaceboplusletrozoleinhormonereceptorpositiveher2negativeadvancedbreastcancer